CD47 and neoplasm: CD47 is expressed at increased level on the cell surface by a variety of malignant cells (Willingham et al,2012); its blockade with monoclonal antibodies allows the efficient phagocytosis of cancer cells and leads to tumor rejection and development of antitumor immunity (Liu et al,2015).